{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:11:39Z","timestamp":1772255499072,"version":"3.50.1"},"reference-count":16,"publisher":"Archives of Endocrinology and Metabolism","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.20945\/2359-3997000000090","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T13:16:23Z","timestamp":1546866983000},"page":"636-640","source":"Crossref","is-referenced-by-count":7,"title":["Rare complications of multikinase inhibitor treatment"],"prefix":"10.20945","volume":"62","author":[{"given":"Fabi\u00e1n","family":"Pitoia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Abelleira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Jerkovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","published-online":{"date-parts":[[2018]]},"reference":[{"issue":"1","key":"key20190107091258_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","unstructured":"1 Haugen BR, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.","journal-title":"Thyroid"},{"issue":"2","key":"key20190107091258_B2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","unstructured":"2 Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134-41.","journal-title":"J Clin Oncol"},{"issue":"9940","key":"key20190107091258_B3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","unstructured":"3 Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-28.","journal-title":"Lancet"},{"issue":"7","key":"key20190107091258_B4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","unstructured":"4 Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621-30.","journal-title":"N Engl J Med"},{"key":"key20190107091258_B5","doi-asserted-by":"crossref","first-page":"985780","DOI":"10.4061\/2011\/985780","article-title":"Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer","volume":"2011","author":"Cabanillas","year":"2011","unstructured":"5 Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res. 2011;2011:985780.","journal-title":"J Thyroid Res"},{"issue":"12","key":"key20190107091258_B6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","unstructured":"6 Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788-95.","journal-title":"Br J Cancer"},{"issue":"2","key":"key20190107091258_B7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1172\/JCI39434","article-title":"Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress","volume":"120","author":"Chintalgattu","year":"2010","unstructured":"7 Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TJ, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 2010;120(2):472-84.","journal-title":"J Clin Invest"},{"issue":"4","key":"key20190107091258_B8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bcp.12387","article-title":"Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials","volume":"78","author":"Qi","year":"2014","unstructured":"8 Qi WX, Shen Z, Tang LN, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol. 2014;78(4):748-62.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"key20190107091258_B9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","volume":"30","author":"Schutz","year":"2012","unstructured":"9 Schutz FAB, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 2012;30(8):871-7.","journal-title":"J Clin Oncol"},{"issue":"6","key":"key20190107091258_B10","doi-asserted-by":"crossref","first-page":"K51","DOI":"10.1530\/EJE-13-0015","article-title":"Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis","volume":"168","author":"Scheffel","year":"2013","unstructured":"10 Scheffel RS, Dora JM, Siqueira DR, Burttet LM, Cerski MR, Maia AL. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. Eur J Endocrinol. 2013;168(6):K51-4.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"key20190107091258_B11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","unstructured":"11 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20190107091258_B12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","unstructured":"12 Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34.","journal-title":"N Engl J Med"},{"issue":"20","key":"key20190107091258_B13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2013.50.7582","article-title":"Extensive squamous cell carcinoma of the skin related to use of sorafenib for treatment of FLT3-mutant acute myeloid leukemia","volume":"34","author":"Fathi","year":"2016","unstructured":"13 Fathi AT, Lin WM, Durazzo T, Piris A, Sadrzadeh H, Bernardo L, et al. Extensive squamous cell carcinoma of the skin related to use of sorafenib for treatment of FLT3-mutant acute myeloid leukemia. J Clin Oncol. 2016;34(20):70-2.","journal-title":"J Clin Oncol"},{"key":"key20190107091258_B14","first-page":"3459","article-title":"Selective use of vandetanib in the treatment of thyroid cancer","volume":"9","author":"Fallahi","year":"2015","unstructured":"14 Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015;9:3459-70.","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"key20190107091258_B15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/hed.21917","article-title":"Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma","volume":"34","author":"Klein","year":"2012","unstructured":"15 Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head Neck. 2012;34(9):1269-76.","journal-title":"Head Neck"},{"issue":"3","key":"key20190107091258_B16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.critrevonc.2013.10.002","article-title":"Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"89","author":"Qi","year":"2014","unstructured":"16 Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2014;89(3):394-403.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T13:16:36Z","timestamp":1546866996000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972018000600636&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018]]}},"alternative-id":["10.20945\/2359-3997000000090"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000090","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}